Background: Mycobacterium tuberculosis is a causative organism of tuberculosis, which is the most deadly disease after cancer in the current decade. The development of multidrug and broadly drug- resistant strains makes the tuberculosis problem more and more critical. In the last 40 years, only one molecule is added to the treatment regimen. Generally, drug design and development programs are targeted proteins whose function is known to be essential to the bacterial cell.

Objectives: Here are the development of 'S', 'N’ heterocycles as antimycobacterials targeting fatty acid biosynthesis are reported.

Materials and Methods: In the present communication, rational development of anti-mycobacterial agent's targeting fatty acid biosynthesis has been done by integrating the pocket modeling and virtual analysis.

Results: The identified potential 33 lead compounds were synthesized, characterized by physicochemical and spectroscopic methods like IR, NMR spectroscopy and further screened for antimycobacterial activity using isoniazid as standard. All the designed compounds have shown profound antimycobacterial activity.

Conclusion: In this present communication, we found that 3c, 3f, 3l and 4k molecules had expressive desirable biological activity and specific interactions with fatty acids. Further optimization of these leads is necessary for the development of potential antimycobacterial drug candidates having fewer side effects.

背景：结核分枝杆菌是结核病的病原体，是近十年来仅次于癌症的最致命的疾病。多药和广泛耐药菌株的发展使结核病问题越来越严重。在过去的 40 年里，只有一种分子被添加到治疗方案中。通常，药物设计和开发程序是靶向蛋白质，其功能已知对细菌细胞至关重要。

目的：这里报告了“S”、“N”杂环作为靶向脂肪酸生物合成的抗分枝杆菌的发展。

材料和方法：在目前的交流中，通过结合口袋建模和虚拟分析，合理开发了抗分枝杆菌药物靶向脂肪酸生物合成。

结果：合成了确定的 33 种潜在先导化合物，通过物理化学和光谱方法（如 IR、NMR 光谱）进行表征，并以异烟肼为标准进一步筛选抗分枝杆菌活性。所有设计的化合物都显示出强大的抗分枝杆菌活性。

结论：在本次交流中，我们发现 3c、3f、3l 和 4k 分子具有表达所需的生物活性和与脂肪酸的特定相互作用。这些先导物的进一步优化对于开发具有较少副作用的潜在抗分枝杆菌候选药物是必要的。